Letter's from the FDA to Lafayette pharmaceutical in which the FDA criticizes Lafayette for not providing regular reports on Pantopaque, and also the FDA ordered Lafayette to change the labeling of Pantopaque and to include warnings of severe reactions it causes namely Adhesive Arachnoiditis.
